RevOpsis Therapeutics Secures $16.5 Million in Seed Funding

May 30, 2024 – I-Corps alumni company RevOpsis Therapeutics recently announced that they secured $16.5 million in seed round funding to advance their macular degeneration treatment. The California-based company previously participated in the Great Lakes I-Corps Hub Jumpstart program. Their innovative medical therapy aims to reduce blindness in individuals affected by Age-related macular degeneration. The new seed funding will accelerate the advancement of the company’s lead asset RO-104 through Investigational New Drug (IND) enabling studies to secure FDA approval for human clinical trials.


The Revopsis team

Members of the RevOpsis team

Co-founded in 2018 by a retina specialist, Dr. Ramanath Bhandari, RevOpsis is utilizing its proprietary Rev-Mod Platform which employs a modular ‘plug-and-play’ approach to streamline and expedite the efficient discovery and development of multi-specific biologics targeting a wide spectrum of chronic, prevalent, large diseases, that are the leading causes of death and disability worldwide. The company’s lead asset RO-104 is a first-in-class fully human modular tri-specific biologic designed to address all three clinically validated dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) implicated in retinal vascular diseases.


RevOpsis’ Innovative Rev-Mod Platform


The company participated in the I-Corps Jumpstart winter program in 2023. The team benefited from valuable instructor feedback and the opportunity to meet and learn from diverse stakeholders in the medical therapeutic industry. This mentorship, along with the insights from the team’s customer discovery interviews, helped the team to chart their path forward. Dr. Bhandari describes what he hopes for the future of RevOpsis:

“Approximately 40% of patients with macular degeneration have a sub-optimal response to current therapies. RevOpsis’ RO-104 as a tri-specific biologic has the potential to be the first monotherapy agent to improve visual outcomes and extend disease remission in patients suffering with macular degeneration.” – Dr. Bhandari, CEO RevOpsis


Learn more about RevOpsis:

Original Press Release